Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases

被引:209
作者
Colombel, Jean-Frederic [1 ]
Narula, Neeraj [2 ,3 ]
Peyrin-Biroulet, Laurent [4 ,5 ]
机构
[1] Icahn Sch Med, Dept Gastroenterol, New York, NY 10029 USA
[2] McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada
[3] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada
[4] Lorraine Univ, Nancy Univ Hosp, Inst Natl Sante & Rech Med U954, Nancy, France
[5] Lorraine Univ, Nancy Univ Hosp, Dept Gastroenterol, Nancy, France
关键词
Intestine; Efficacy; Dose; Control; ANTI-SACCHAROMYCES-CEREVISIAE; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; SUBCLINICAL INTESTINAL INFLAMMATION; C-REACTIVE PROTEIN; CROHNS-DISEASE; ULCERATIVE-COLITIS; LONG-TERM; FECAL CALPROTECTIN; DIAGNOSTIC DELAY; CLINICAL REMISSION;
D O I
10.1053/j.gastro.2016.09.046
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Strategies for management of inflammatory bowel diseases are shifting from simple control of symptoms toward full control of these diseases (clinical and endoscopic remission), with the final aim of blocking their progression and preventing bowel damage and disability. New goals have been proposed for treatment, such as treat to target and tight control based on therapeutic monitoring and early intervention. For patients who achieve clinical remission, there is often interest in discontinuation of therapy due to safety or economic concerns. We review the evidence supporting these emerging paradigms, the reasons that early effective treatment can alter progression of inflammatory bowel diseases, the importance of examining objective signs of inflammation, and the safety of reducing treatment dosage. We also discuss recent findings regarding personalization of care, including factors that predict patient outcomes and response to therapies, as well as preventative strategies.
引用
收藏
页码:351 / +
页数:16
相关论文
共 153 条
[1]   Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis [J].
Adedokun, Omoniyi J. ;
Sandborn, William J. ;
Feagan, Brian G. ;
Rutgeerts, Paul ;
Xu, Zhenhua ;
Marano, Colleen W. ;
Johanns, Jewel ;
Zhou, Honghui ;
Davis, Hugh M. ;
Cornillie, Freddy ;
Reinisch, Walter .
GASTROENTEROLOGY, 2014, 147 (06) :1296-+
[2]   Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis [J].
Ahmad, Tariq ;
Basavaraju, Umesh ;
Basquill, Catriona ;
Cameron, Fiona L. ;
Christodoulou, Christos ;
Cummings, Fraser ;
Ding, Nik S. ;
Fadra, Adam S. ;
Flanders, Lucy ;
Gaya, Daniel R. ;
Gooding, Ian ;
Gordon, John ;
Grieveson, Kay ;
Harris, Richard ;
Hart, Ailsa ;
Hendy, Philip ;
Irving, Peter ;
Johnston, Emma L. ;
Johnston, Matthew ;
Kennedy, Nicholas A. ;
Lal, Simon ;
Lamb, Christopher A. ;
Lees, Charlie W. ;
Lindsay, James O. ;
Lithgo, Karen ;
Lockett, Melanie ;
Maggs, Daniel ;
Mann, Steve ;
Mansfield, John ;
Mason, Joy ;
McCartney, Sara ;
Murray, Charles D. ;
Nowell, Emma ;
Parkes, Miles ;
Russell, Richard K. ;
Satsangi, Jack ;
Singh, Abhey ;
Stansfield, Catherine ;
Thomson, John ;
Warner, Ben ;
Wilson, David C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (08) :910-923
[3]  
Allez M, 2002, AM J GASTROENTEROL, V97, P947
[4]   Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis:: A GISC study [J].
Annese, V ;
Andreoli, A ;
Andriulli, A ;
D'Inca, R ;
Gionchetti, P ;
Latiano, A ;
Lombardi, G ;
Piepoli, A ;
Poulain, D ;
Sendid, B ;
Colombel, JF .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (08) :2407-2412
[5]   A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis [J].
Arias, Maria Theresa ;
Casteele, Niels Vande ;
Vermeire, Severine ;
van Overstraeten, Anthony de Buck ;
Billiet, Thomas ;
Baert, Filip ;
Wolthuis, Albert ;
Van Assche, Gert ;
Noman, Maja ;
Hoffman, Ilse ;
D'Hoore, Andre ;
Gils, Ann ;
Rutgeerts, Paul ;
Ferrante, Marc .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (03) :531-538
[6]   Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis [J].
Arijs, I. ;
Li, K. ;
Toedter, G. ;
Quintens, R. ;
Van Lommel, L. ;
Van Steen, K. ;
Leemans, P. ;
De Hertogh, G. ;
Lemaire, K. ;
Ferrante, M. ;
Schnitzler, F. ;
Thorrez, L. ;
Ma, K. ;
Song, X. -Y R. ;
Marano, C. ;
Van Assche, G. ;
Vermeire, S. ;
Geboes, K. ;
Schuit, F. ;
Baribaud, F. ;
Rutgeerts, P. .
GUT, 2009, 58 (12) :1612-1619
[7]   Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype [J].
Arnott, IDR ;
Landers, CJ ;
Nimmo, EJ ;
Drummond, HE ;
Smith, BKR ;
Targan, SR ;
Satsangi, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (12) :2376-2384
[8]   Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation [J].
Baars, Judith E. ;
Nuij, Veerle J. A. A. ;
Oldenburg, Bas ;
Kuipers, Ernst J. ;
van der Woude, Christien J. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) :1634-1640
[9]   Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease [J].
Baert, Filip ;
Moortgat, Liesbeth ;
Van Assche, Gert ;
Caenepeel, Philip ;
Vergauwe, Philippe ;
De Vos, Martine ;
Stokkers, Pieter ;
Hommes, Daniel ;
Rutgeerts, Paul ;
Vermeire, Severine ;
D'Haens, Geert .
GASTROENTEROLOGY, 2010, 138 (02) :463-468
[10]   Predictors of Crohn's disease [J].
Beaugerie, L ;
Seksik, P ;
Nion-Larmurier, I ;
Gendre, JP ;
Cosnes, J .
GASTROENTEROLOGY, 2006, 130 (03) :650-656